VEGFA and meningioma: The treatment of grade 3 meningiomas is based on surgery and radiotherapy; however, new systemic agents, namely tyrosine kinase inhibitors and monoclonal antibodies targeting vascular endothelial growth factor (VEGF), have been developed and are under further investigation [135,136,137,138,139].